BSW Wealth Partners Has $323,000 Holdings in Danaher Corporation (NYSE:DHR)

BSW Wealth Partners decreased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 57.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,575 shares of the conglomerate's stock after selling 2,138 shares during the quarter. BSW Wealth Partners' holdings in Danaher were worth $323,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Fortis Capital Advisors LLC boosted its position in Danaher by 1.3% during the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after acquiring an additional 50 shares during the period. Fayez Sarofim & Co raised its position in shares of Danaher by 0.6% during the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after buying an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC lifted its stake in shares of Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after acquiring an additional 50 shares during the period. Perennial Investment Advisors LLC boosted its holdings in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after acquiring an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC increased its stake in shares of Danaher by 3.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after acquiring an additional 52 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

NYSE DHR traded up $4.17 on Tuesday, reaching $201.71. The stock had a trading volume of 2,178,048 shares, compared to its average volume of 4,273,394. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The company has a market cap of $144.35 billion, a P/E ratio of 39.16, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The firm has a fifty day moving average of $195.09 and a two-hundred day moving average of $207.89.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. On average, equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.63%. Danaher's payout ratio is 24.85%.

Insider Buying and Selling at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.20% of the company's stock.

Analyst Upgrades and Downgrades

DHR has been the subject of several research reports. The Goldman Sachs Group reduced their price objective on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Wells Fargo & Company reduced their target price on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating for the company in a report on Wednesday, April 23rd. Wolfe Research decreased their price target on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research report on Monday, April 7th. Deutsche Bank Aktiengesellschaft reduced their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Barclays reissued an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.